PARP Inhibitors Gain a Foothold in Prostate Cancer

Danielle Ternyila
Published: Thursday, Dec 12, 2019
Alan Bryce, MD, associate professor of medicine at the Mayo Clinic

Alan Bryce, MD

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC), targeted therapy had an uncertain foothold in this tumor type. Alan Bryce, MD, associate professor of medicine at the Mayo Clinic in Rochester, Minnesota, speculated that olaparib will likely herald a new class of drugs in the treatment of prostate cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x